Glenmark's Novel Antibody GBR 1302 to Enter Clinical Trials

New Delhi: Glenmark Pharmaceuticals has completed the pre-clinical evaluation for its novel bi-specific antibody GBR 1302 and filed the phase I trial application for the same with German regulatory authorities. Glenmark Pharmaceuticals SA, a wholly-owned subsidiary of the company, has submitted a clinical trial application for GBR 1302 to the Paul-Ehrlich Institute in Germany, Glenmark Pharmaceuticals said in a statement. GBR 1302 ...